What Is Atosiban?
Atosiban is a uterine-specific mixed vasopressin V1A and oxytocin-receptor antagonist. It is registered for tocolysis in imminent premature birth, but it has also been investigated in assisted reproductive technology, especially around embryo transfer. The interest comes from its ability to reduce uterine contractility, which may help create a more favorable uterine environment. Because embryo transfer success depends not only on embryo quality but also on endometrial receptivity and embryo–endometrium dialogue, atosiban has attracted attention as a supportive intervention in selected fertility-treatment settings.
Why Uterine Contractions Matter
Embryo transfer is one of the critical steps in assisted reproduction, yet success per cycle remains limited. The reviewed article notes that ideal endometrial receptivity depends on appropriate endometrial status, sufficient perfusion, and the absence of excessive uterine contractions. Increased contractions have been reported in approximately 30% of patients undergoing embryo transfer, and excessive contractions may expel transferred embryos from the uterus. This provides the biological rationale for studying atosiban before or around embryo transfer: lowering contraction frequency and amplitude could potentially improve implantation conditions.
Evidence from Meta-Analysis
A systematic review and meta-analysis evaluated studies comparing atosiban with placebo or no treatment at the time of embryo transfer. The analysis included four randomized controlled trials with 1,025 women and two non-randomized trials with 686 patients. Atosiban was associated with increased clinical pregnancy rates in both groups of evidence. In randomized trials, the pooled odds ratio was 1.47 with a 95% confidence interval of 1.18–1.82; in non-randomized trials, it was 1.50 with a 95% confidence interval of 1.10–2.05.
Dosing Approaches Studied
The studies used intravenous atosiban before embryo transfer, either as a single bolus or as a bolus followed by infusion. Several protocols used a 6.75 mg IV bolus around 30 minutes before embryo transfer, sometimes followed by 18 mg/h infusion and then 6 mg/h after transfer, with total doses around 36.75–37.5 mg. Another trial used 7.5 mg by slow IV injection. These regimens reflect research protocols rather than a universal standard, so clinical use should follow local guidance and specialist judgment.
Practical Value and Limitations
The review concluded that atosiban appears to increase clinical pregnancy rates in women undergoing embryo transfer. However, the authors also emphasized limitations: only six studies were included, heterogeneity was moderate, and the quality of most studies was low to moderate because of unclear selection, performance, or detection bias. Practical barriers also matter. Atosiban requires peripheral venous catheterization, may prolong hospitalization, and can increase embryo-transfer costs. Its role is therefore promising, but still best interpreted as an evidence-informed option rather than a guaranteed solution.
If you are looking for a high-quality peptide manufacturer with whom you can establish a long-term, stable partnership, then Shaanxi Medibridge Biotech Co., Ltd. would be your ideal choice. Please feel free to contact us at hi@medibridgeapi.com.
